Andere talen Daré Bioscience, Inc.

Aandelen

DARE

US23666P2002

Farmaceutische producten

Beurs gesloten - Nasdaq Andere beurzen 21:39:22 18-06-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,880 ^USD	-0,17%		-7,69%	-7,69%

05/06	Top stijgers voor beurs	MT
27/05	Daré Bioscience, Inc., Q1 2025 Earnings Call, May 13, 2025

Andere talen

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders	12/06
Top Premarket Gainers	05/06
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream	04/06
Daré Bioscience Reports First Quarter 2025 Financial Results And Provides Company Update	13/05
Daré Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	13/05
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update	13/05
Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025	06/05
Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation	23/04
Wall Street Set to Open Mixed Thursday as Investors Parse Key Employment, Manufacturing Data	17/04
Investors Await Key Employment, Manufacturing Data as US Futures Mixed in Thursday's Premarket	17/04
Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year	07/04
Daré Bioscience Reports Full Year 2024 Financial Results	31/03
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update	31/03
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	31/03
Daré Bioscience, Inc. Auditor Raises 'Going Concern' Doubt	31/03
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025	24/03
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant	20/02
Dare Bioscience and Theramex Announce Co-Development and Licensing Agreement for A Potential Biodegradable Long-Acting Contraceptive Implant	20/02
Dare Bioscience Announces Funding Award Notice from the National Institutes of Health National Institute of Allergy and Infectious Diseases to Support DARE-HPV Development	07/02
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development	06/02
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference	09/01
Dare Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder	17/12
Dare Bioscience to Submit Plan for Phase 3 Study of Potential Female Sexual Disorder Treatment	16/12
Dare Bioscience : Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) Form 8 K	16/12
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)	16/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Daré Bioscience, Inc.

Aandelen

DARE

US23666P2002

Farmaceutische producten

Andere talen

Filters